These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 8893893

  • 1. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
    Piccart-Gebhart MJ, Bruning P, Gamucci T, Klijn J, Roy JA, Awada A, Kusenda Z, Van Vreckem A, Paridaens R.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):11-5. PubMed ID: 8893893
    [Abstract] [Full Text] [Related]

  • 2. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 3. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [Abstract] [Full Text] [Related]

  • 4. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BW, Ejlertsen B.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R.
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hecker D, Diergarten K.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Tienghi A, Ravaioli A, Casadei Giunchi D, Gentile A, Salzano E.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):19-23. PubMed ID: 8629031
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer.
    Dieras V, Marty M, Tubiana N, Corette L, Morvan F, Serin D, Mignot L, Chazard M, Garet F, Onetto N.
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):33-9. PubMed ID: 7638640
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
    Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M.
    J Clin Oncol; 2000 Feb; 18(4):724-33. PubMed ID: 10673513
    [Abstract] [Full Text] [Related]

  • 14. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW.
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):123-5; discussion 126-9. PubMed ID: 7481854
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
    Vermorken JB, ten Bokkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijnen JH, Bierhorst F, Winograd B, Pinedo HM.
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):16-22. PubMed ID: 7543699
    [Abstract] [Full Text] [Related]

  • 17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 18. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [Abstract] [Full Text] [Related]

  • 19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 20. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Frassineti GL, Zoli W, Tienghi A, Ravaioli A, Milandri C, Gentile A, Salzano E, Amadori D.
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):22-8. PubMed ID: 8941407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.